期刊文献+

切割Fas mRNA核酶的构建及其体内外切割活性的鉴定 被引量:1

Construction of Anti-Fas Ribozyme and Characterization of Its Cleavage Activities in vitro and in vivo
在线阅读 下载PDF
导出
摘要 白血病细胞表面可高表达FasL ,诱导表达Fas的T细胞凋亡 ,从而降低其抗白血病的作用 .以高表达Fas的小鼠淋巴瘤细胞系Yac 1作为模型 ,设计并合成了针对FasmRNA 5 96位点的锤头状核酶基因 ,用T7/SP6体外转录系统检测了该核酶对FasmRNA的体外切割效率 ,通过电穿孔转染法将其导入Yac 1细胞 ,通过RT PCR、Western印迹法检测细胞上Fas的表达 .细胞经抗Fas的抗体作用后 ,通过MTT法测细胞的增殖 ,annexin Ⅴ凋亡检测试剂盒测细胞凋亡 .该核酶体外切割活性达6 0 % ,且能有效降低细胞表面Fas的表达 ;细胞经抗Fas的抗体作用后 ,转染核酶的细胞增殖活性较对照增高 ,而凋亡率明显降低 .结果表明 ,构建的切割FasmRNA核酶在体内外均具备良好的切割FasmRNA的活性 ,使细胞免于Fas途径的凋亡 ,为研究抑制T细胞的凋亡从而增强其抗白血病效应提供实验基础 . Based on the fact that tumor cells expressing FasL can induce apoptosis of T cells expressing Fas and reduce their anti-tumor activity,mouse lymphoma cell line-Yac-1 highly expressing Fas was used as a model.A hammerhead ribozyme targeting position 596 of the Fas mRNA was synthesized and its in vitro transcription was constructed,which was transfected into Yac-1 cells by electroporation.Fas expression on Yac-1 cells was detected by RT-PCR and Western blotting.After being treated with anti-Fas antibody(JO2),Yac-1 cells viability was measured by MTT assay.Cells apoptosis was measured according to FITC labeled annexin-V apoptosis detecting kit.In vitro cleavage activity fo anti-Fas ribozyme was 60% and could decrease Fas expression on Yac-1 cells efficiently.Treated with anti-Fas antibody(JO2),apoptosis rates of cells transfected with ribozyme decreased remarkably and cells viability was enhanced compared with the control.The ribozyme cleaved Fas excellently in vitro and in vivo and made cells get rid of Fas-mediated apoptosis,which is very helpful for inhibiting apoptosis of T cells and enhancing its anti-tumor effects.
出处 《中国生物化学与分子生物学报》 CAS CSCD 北大核心 2004年第5期643-647,共5页 Chinese Journal of Biochemistry and Molecular Biology
基金 国家自然科学基金资助项目 (No .3 0 2 40 0 2 2 )资助课题~~
关键词 核酶 FAS Yac-1 凋亡 肿瘤免疫 ribozyme,Fas, Yac-1,apoptosis,tumor immunity
  • 相关文献

参考文献9

  • 1[1]Costello R T, Rey J, Fauriat C, Gastaut J A, Olive D. New approaches in the immunotherapy of haematological malignancies, Eur J Haematol,2003,70: 333 ~ 345
  • 2[2]Goodchild J. Hammerhead ribozymes: Biochemical and chemical considerations. Curr Opin Mol Ther, 2000,2: 272 ~ 281
  • 3[3]Takagi Y, Warashina M, Stec W J, Yoshinari K, Taira K. Survey and summary: Recent advances in the elucidation of the mechanisms of action of ribozymes. Nucleic Acids Res, 2001,29:1815 ~ 1834
  • 4[4]Jaeger J A, Turner D H, Zucker M. Improved predications of secondary structures for RNA. Proc Natl Acad Sci USA, 1989,86:7706 ~ 7710
  • 5[5]Klein D, Denis M, Ricordi C, Pastori R L. Assessment of ribozyme cleavage efficiency using reverse transcriptase real-time PCR. Mol Biotechnol, 2000,14:189 ~ 195
  • 6[6]Schattner E J, Friedman S M, Casali P. Inhibition of Fas-mediated apoptosis by antigen: implications for lymphomagenesis. Autoimmunity,2002,35: 283 ~ 289
  • 7[7]Mousses S, Caplen N J, Comerlison R, Weaver D, Basik M, Hautaniemi S,Elkahloun A G, Lotufo R A, Choudary A, Dougherty E R, Suh E,Kallioniemi O. RNAi Microarray Analysis in Cultured Mammalian Cells.Genome Res, 2003,13: 2341 ~ 2347
  • 8[8]Klein D, Ricordi C, Pugliese A, Pastori R L. Inhibition of Fas-mediated apoptosis in mouse insulinoma βTC-3 cells via an anti-Fas ribozyme.Hum Gene Ther, 2000,11:1033 ~ 1045
  • 9[9]Al-Anouti F, Ananvoranich S. Comparative analysis antisense RNA,double-stranded RNA, and delta ribozyme-mediated gene regulation in Toxoplasma gondii. Antisense Nucleic Acid Drug Dev, 2002,12: 275 ~ 281

同被引文献17

  • 1侯化,金由辛.Ribozyme在基因治疗中的研究进展[J].医学信息(医学与计算机应用),2000,13(5):265-267. 被引量:3
  • 2侯丙凯,于惠敏.Ribozyme在疾病治疗中的应用[J].国外医学(遗传学分册),1995,18(4):202-203. 被引量:1
  • 3毛建平,王全会,韩慧明,袁国刚,左刚,邵世和,毛秉智.10-23型DNA酶作为鉴定mRNA靶点有效性的新工具[J].中国生物化学与分子生物学报,2005,21(5):622-627. 被引量:4
  • 4王全会,左刚,施水兰,赵增强,崔玉芳,毛建平.10-23型脱氧核酶对mRNA表达的双重抑制作用[J].军事医学科学院院刊,2005,29(6):531-534. 被引量:1
  • 5刘芳,邹萍,吴耀辉,易雪.锤头状核酶对转化生长因子β1 RNA的体外剪切作用[J].中国生物化学与分子生物学报,2006,22(1):59-62. 被引量:1
  • 6Levon M Khachigian, Ravinay Bhindi, Roger G Fahmy, et al. DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. The American Journal of Pathology, 2007, 171 (4) : 1079-1088.
  • 7Ronald T Mitsuyasu, Thomas C Merigan, Andrew Carr, et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34^+ cells. Nature Medicine, 2009, 15(3) : 285-292.
  • 8Michel V Le'vesque, Dominique Le'vesque, Francis P Brie're, et al. Investigating a new generation of ribozymes in order to target HCV. PLoS ONE. 2010, 5(3) : e9627.
  • 9David C Bloom, Jia Liu, Alfred S Lewin, et al. Reduction in severity of a herpes simplex virus type 1 murine infection by treatment with a ribozyme targeting the UL20 gene RNA. J Virol, 2008, 82(15) : 7467-7474.
  • 10Carol A Kruse, Richard Tritz, Cellia Habita, et al. Catalytic nucleic acid enzymes for the study and development of therapies in the central nervous system: review article. Gene Ther Mol Biol, 2005, 9A: 89-106.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部